• Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference

    来源: Nasdaq GlobeNewswire / 06 8月 2024 06:59:00   America/New_York

    CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13th, 2024 at 2:30 p.m. ET in Boston.

    A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.

    About Generation Bio

    Generation Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.

    For more information, please visit www.generationbio.com.

    Investors and Media Contact
    Maren Killackey
    Generation Bio
    mkillackey@generationbio.com
    857-371-4638


    Primary Logo

分享